Welcome to our dedicated page for BrightSpring Health Services news (Ticker: BTSG), a resource for investors and traders seeking the latest updates and insights on BrightSpring Health Services stock.
BrightSpring Health Services, Inc. (BTSG) delivers integrated home and community-based healthcare through pharmacy solutions and clinical services. This page provides investors and industry professionals with timely, centralized access to official announcements and market developments.
Track critical updates including quarterly earnings, strategic acquisitions, partnership agreements, and service expansions. Our curated collection ensures you stay informed about operational milestones across BTSG's pharmacy networks and home health divisions.
Discover verified information on Medicare/Medicaid program developments, clinical quality initiatives, and geographic expansions. All content is sourced directly from company filings and authorized communications to maintain accuracy.
Bookmark this page for efficient monitoring of BTSG's evolving role in complex care management. Check regularly for updates on how the company addresses challenges in specialty pharmacy and community-based care delivery.
BrightSpring Health Services (NASDAQ: BTSG) announced that its subsidiary, Onco360®, has been selected as the national pharmacy partner for OJEMDA™, a newly FDA-approved treatment for pediatric low-grade glioma (LGG) with BRAF mutations. This partnership with Day One Biopharmaceuticals aims to provide this cutting-edge, once-weekly oral medication to children aged six months and older who have relapsed or refractory LGG. The approval is based on the FIREFLY-1 clinical trial, and ongoing confirmatory trials are required for continued approval. Onco360® offers specialized oncology medications and support services, including financial assistance, clinical counseling, and insurance verification.
BrightSpring Health Services, Inc. reported strong financial results for Q1 2024, with net revenue of $2,577 million, a 27.0% increase from Q1 2023. The company's Adjusted EBITDA was $131 million, up 13.2% year-over-year. BrightSpring appointed Timothy Wicks to the Board of Directors and increased its 2024 revenue and Adjusted EBITDA guidance. The company is optimistic about its outlook for the year, citing growth in both Pharmacy and Provider segments.
FAQ
What is the current stock price of BrightSpring Health Services (BTSG)?
What is the market cap of BrightSpring Health Services (BTSG)?
